← Human Trials & Peer-Reviewed Studies
A randomized, double-blind, placebo-controlled study to assess the efficacy and safety of cinacalcet in pediatric patients with chronic kidney disease and secondary hyperparathyroidism receiving dialysis
Plain-language guide to PMID 30506144 (2019): double-blind randomized controlled trial study of Parathyroid Hormone (PTH 1-84), hyperparathyroidism.
Key Facts
- PMID
- 30506144
- Journal
- Pediatric nephrology (Berlin, Germany)
- Year
- 2019
- Study type
- Randomized Controlled Trial
- Authors
- Warady BA et al. (10 authors)
- DOI
- 10.1007/s00467-018-4116-y
What This Study Did, in Plain Language
What Was Tested
This randomized controlled trial paper looks at Parathyroid Hormone (PTH 1-84) in the context of hyperparathyroidism.
Who Took Part
The age groups tagged for this paper are children and teenagers, both men and women.
How the Study Was Run
The design is described as randomized, double-blind, open-label and placebo-controlled.
Random assignment meant chance, not the researchers, decided who got Parathyroid Hormone (PTH 1-84) and who got the comparison, which limits bias.
As a double-blind Parathyroid Hormone (PTH 1-84) study, the assignments were hidden from both participants and investigators until the end.
Being open-label, the Parathyroid Hormone (PTH 1-84) study did not mask who received what.
The comparison arm used a placebo, so changes seen with Parathyroid Hormone (PTH 1-84) could be set against what happens without it.
This study had double-blind and open-label phases.
Secondary endpoints included mean iPTH ≤ 300 pg/mL; percentage change from baseline in corrected total serum calcium, phosphorus, and calcium phosphorus product (Ca × P); and safety.
What Was Measured
PubMed files the paper under topics including Calcimimetic Agents, Calcium, Cinacalcet, Hyperparathyroidism, Secondary, Hypertension, Hypocalcemia and Nausea.
Author keywords: Calcimimetics, Chronic kidney disease, Parathyroid hormone, Pediatric patients and Secondary hyperparathyroidism.
What This Means in Plain Language
The paper is a randomized, double-blind and open-label study of Parathyroid Hormone (PTH 1-84) in people with hyperparathyroidism.
Results are reported in around 7 sentences of the abstract; we leave them to the paper itself rather than summarise them.
The publication is from 2019 (Pediatric nephrology (Berlin, Germany)), a journal based in Germany.
More context: the Parathyroid Hormone (PTH 1-84) compound page, Hyperparathyroidism research.
Our Notes on the Compound
Parathyroid Hormone (PTH 1-84): The 84-amino-acid hormone that raises blood calcium; full-length PTH (Natpara) has been used in hypoparathyroidism. Teriparatide is its 1-34 fragment.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.